Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZLNAP)

Drug Name

1-(4-fluorophenyl)-2-(phenylsulfonyl)ethanone Drug Info

Synonyms

CHEMBL238832; 41024-58-2; Ethanone, 1-(4-fluorophenyl)-2-(phenylsulfonyl)-; 1-(4-fluorophenyl)-2-(phenylsulfonyl)-1-ethanone; 1-(4-fluorophenyl)-2-(phenylsulfonyl)ethanone; AC1LS74Y; CTK1D4107; DTXSID90363277; MolPort-002-876-867; ZINC1396918; BDBM50212525; AKOS005098035; MCULE-9386710722; 7H-334S; KS-00001Z92; 4'-Fluoro-alpha-(phenylsulfonyl)acetophenone; 2-(benzenesulfonyl)-1-(4-fluorophenyl)ethanone

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 1483401
CAS Number: CAS 41024-58-2
TTD Drug ID: DMZLNAP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GLYCYRRHIZIN	DM8M2N3	Influenza virus infection	1E30-1E32	Phase 3	[2]
BVT.2733	DM6RUKX	Lupus	4A40	Phase 3	[3]
INCB13739	DMLQ3PO	Type-2 diabetes	5A11	Phase 2a	[4]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[5]
JTT-654	DM50M2R	Type-2 diabetes	5A11	Phase 2	[6]
RG-4929	DMT4QRD	Metabolic disorder	5C50-5D2Z	Phase 2	[6]
BMS-770767	DMTVGY7	Hypercholesterolaemia	5C80.0	Phase 2	[6]
UE-2343	DMIERPK	Alzheimer disease	8A20	Phase 2	[7]
AZD-4017	DML9M5S	Ocular hypertension	9C61.01	Phase 2	[6]
Xanamem	DM580GT	Alzheimer disease	8A20	Phase 1/2	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)	TTN7BL9	DHI1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405.
2	Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32.
3	Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62.
4	Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008.
5	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
6	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem?). Br J Pharmacol. 2017 Mar;174(5):396-408.